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Background: Hepatitis E virus (HEV), an enterically transmitted pathogen, is highly endemic in several African
countries. Pregnant women are at particularly high risk for acute or severe hepatitis E. In Gabon, a central African
country, the prevalence of antibodies to HEV among pregnant women is 14.1%. Recent studies have demonstrated
unusual patterns of hepatitis E (chronic hepatitis, cirrhosis) among immunodeficient patients.
Findings: We investigated the prevalence of antibodies to HEV among pregnant women infected with HIV-1 or
HTLV-1 in Gabon. Of 243 samples collected, 183 were positive for HIV-1 and 60 for HTLV-1; 16 women (6.6%) had
IgG antibodies to HEV. The seroprevalence was higher among HIV-1-infected women (7.1%) than HTLV-1-infected
women (5.0%). Moreover, the HIV-1 viral load was significantly increased (p ≤ 0.02) among women with past-HEV
exposure (1.3E+05 vs 5.7E+04 copies per ml), whereas no difference was found in HTLV-1 proviral load (9.0E+01 vs
1.1E+03 copies per ml).
Conclusions: These data provide evidence that HIV-1-infected women are at risk for acute or severe infection if
they are exposed to HEV during pregnancy, with an increased viral load.
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Hepatitis E virus (HEV) is an enterically transmitted
pathogen that causes widescale epidemics of acute hepa-
titis in highly HEV-endemic areas such as Africa, Asia and
the Middle East [1]. Sporadic cases are also observed in
Europe, Japan, Russia and the USA, where HEV is spread
mainly by zoonotic foodborne transmission [2]. Although
perinatal and bloodborne transmission may occur, the
main route of HEV transmission worldwide remains
ingestion of fecal-contaminated water [3].
Many HEV outbreaks have been described in Africa,
such as that recently observed in Uganda, with over 10
000 cases of acute hepatitis and 160 deaths [4]. The
prevalence of antibodies to HEV varies widely in Africa,
from 4.4% in the rural population of Ghana to 84.3%
among pregnant women in Egypt [5,6]. In a previous
study, we found a prevalence of 14.1% among pregnant
women in Gabon [7].* Correspondence: mirdad.kazanji@pasteur.fr
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reproduction in any medium, provided the orHEV is responsible for self-limiting or acute hepatitis,
the severity ranging from benign to fulminant forms [8].
Hepatitis E is associated with a mortality rate of ≤ 4%, in
particular among young adults, and up to 20% among
pregnant women [9]. Obstetric complications due to
HEV infection might be partly explained by hormonal
changes and immune factors [10]. A study on maternal
and fetal outcomes in India showed that pregnant
women with acute hepatitis E had a 2.7 times higher
relative risk for fulminant hepatic failure and a 6.0 times
higher risk for mortality [11].
Persistent carriage of HEV has been described re-
cently, with cases of chronic hepatitis and cirrhosis
among organ-transplant recipients under immunosup-
pressive therapy [12-14]. In studies of acute hepatitis E
among HIV-1-infected patients [15,16], it has been sug-
gested that hepatitis E can become chronic in people
with severe immunodeficiency [17]. Long-term carriage
of HEV might therefore warrant increased awareness
and vigilance in cases of HIV-1 infection.
Previous studies conducted by our group among preg-
nant women in Gabon showed that the prevalence of
HIV-1 infection is 6.3% and that of another humantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(HIV-1 and HTLV-1) have identical modes of transmis-
sion (sexual) and induce immunological disorders. As
co-infections might occur in populations that are highly
exposed to common risk factors and co-infection of a
woman with a pre-existing infection with HIV-1 or
HTLV-1 might increase the severity of disease, we
investigated the prevalence of antibodies to HEV among
HIV-1- and HTLV-1-infected pregnant women in
Gabon. A cohort of 243 pregnant women was followed
at the International Centre for Medical Research in
Franceville, Gabon. Blood samples were collected an-
onymously, and only sociodemographic data were
retained after informed consent. The study obtained eth-
ical clearance from the Gabonese public health author-
ities (Ministry of Health) and from the Gabonese
scientific and national ethical committees (Authorization
no 093/MSP/SG/SGAQM).
After serological and confirmation assays for diagnosis of
HIV-1 and HTLV-1/2, the HIV-1 viral load was determined
with “Generic HIV Charge Viral (Biocentric, France)” and
the HTLV-1 proviral load as previously described by Besson
et al. [20]. IgG antibodies to HEV were measured with an
ELISA (TMB) Kit (Genelabs Diagnostics, Singapore)
according to the manufacturer’s instructions. None of preg-
nant women in our study was co-infected with HIV-2,
HTLV-2, HBV/HDV or HCV. Statistical analyses were con-
ducted with STATA 11.0 software.
Of the 243 pregnant women, 183 were infected with
HIV-1 and 60 with HTLV-1 (Table 1). The mean age of
the study population was 28.2 ± 6.5 years (range, 14–43
years). The mean age of the HIV-1-infected women was
27.9 ± 6.2 years (range, 15–43 years), and the median viral
load was 6.1E+04 copies per ml (first quartile, 1.5E+04
copies per ml; third quartile, 2.6E+05 copies per ml). The
mean age of the HTLV-1-infected women was 29.1 ± 7.1
years (range, 16–42 years), and the median proviral loadTable 1 Viral status by prevalence of antibodies to hepatitis E
Africa
Viral status HEV status No. (%) Mean age (years) (
HIV-1+ HEV+ 13 26.3 (4.5)
HEV– 170 28.0 (6.3)
Total 13/183 (7.1) 27.9 (6.2)
HTLV-1+ HEV+ 3 33.7 (5.4)
HEV– 57 28.8 (7.1)
Total 3/60 (5.0) 29.1 (7.1)
Total HEV+ 16 27.8 (5.5)
HEV– 227 28.2 (6.5)
Total 16/243 (6.6) 28.2 (6.5)
HEV+: IgG antibodies to HEV in serum; HIV-1, human immunodeficiency virus type 1
women; SD, standard deviation; [FQ–TQ], first quartile–third quartile; NS, not signific
Significance level (p < 0.05) calculated with Student t test for age, Fisher exact test
distribution was not normal.was 9.3E+02 copies per ml (first quartile, 2.7E+02 copies
per ml; third quartile, 3.8E+03 copies per ml).
Sixteen of the 243 pregnant women (6.6%) had IgG
antibodies to HEV (Table 1). The seroprevalence did not
depend significantly on viral status (HIV-1 positive or
HTLV-1-positive) or age. HTLV-1-infected women with
past exposure to HEV had lower proviral loads than
those without past exposure. Nevertheless, the sample
size and seroprevalence in this population were low,
making it difficult to detect a significant difference. Con-
versely, the seroprevalence tended to increase with HIV-
1 viral load (p ≤ 0.02 with the Cuzick non-parametric
test for trend [21]), when HIV-1 status was stratified into
three groups: uninfected and HIV-1 positive, HIV-1
positive with viral load ≤ median and HIV-1 positive,
HIV-1 positive with viral load > median and HIV-1 posi-
tive (Table 1, Figure 1). HIV-1-infected women with a
high viral load were at higher risk for acute or severe
hepatitis E.
Previously, we found HEV prevalences of 6.4% in rural
and 13.5% in urban Gabonese pregnant women, which
were significantly different (p < 0.05) [7]. In this study, we
found that the risk for HEV infection of pregnant women
infected with HIV-1 or HTLV-1 was similar to that of
women living in rural areas. This finding corroborates our
previous report of endemic HEV circulation in Gabon and
indicates active autochthonous HEV transmission among
women of reproductive age. While no effect of past HEV
exposure was found on the prevalence of HTLV-1 infec-
tion, an increased prevalence of antibodies to HEV was
associated with a high HIV-1 load.
It is possible that HIV-1 infection predisposes to HEV ac-
quisition, as suggested in a study in the Russian Federation,
which showed an association between a higher HEV preva-
lence and more advanced HIV-1 related disease [22]. Re-
cently, persistent carriage of HEV has been observed
among patients with HIV-1 infection. This might usually bevirus (HEV) among pregnant women in Gabon, central
SD) p Median viral load (copies/ml) [FQ-TQ] p
NS 1.3E+05 [5.1E+04-9.2E+05] ≤ 0.02
5.7E+04 [1.5E+04-2.4E+05]
6.1E+04 [1.5E+04-2.6E+05]






; HTLV-1, human T-cell leukemia virus type 1; No., number of pregnant
ant; –, not done.
for viral status, and Wilcoxon-Mann–Whitney test for viral load, as the
Figure 1 Odds ratios for having IgG antibodies to hepatitis E virus (HEV) by human immunodeficiency virus (HIV-1) status and viral
load.
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among patients receiving antiretroviral therapy [23]. HEV
infection could, however, represent a differential diagnosis
of hepatitis in pregnancy [24]. As in our study, most HIV-
1-infected pregnant women do not have HEV antibodies,
placing them at increased risk for acute or severe hepatitis
E in an area endemic for both viruses.
HIV-1-infected pregnant women in Gabon appear to
have a specific risk for HEV acquisition, with an increased
viral load. No studies of hepatitis E have been conducted
in the general population of Gabon, and the sources of in-
fection remain unknown. In conclusion, HEV might be an
important unrecognized cause of fatal hepatitis, particu-
larly among HIV-1-positive pregnant women.
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